Browse by Tumor Type
All FDA-actionable biomarkers grouped by indication
Non-small cell lung cancer
17 biomarkers- ●EGFR exon 19 deletion
- ●EGFR L858R
- ●EGFR T790M
- ●KRAS G12C
- ●BRAF V600E
- +12 more
Colorectal cancer
11 biomarkers- ●BRAF V600E
- ●MSI-H / dMMR
- ●KRAS G12C (colorectal cancer)
- ●BRAF V600E (colorectal cancer)
- ●KRAS any mutation (colorectal)
- +6 more
Breast cancer
11 biomarkers- ●BRCA1/2 pathogenic variant
- ●HER2 amplification / overexpression
- ●PIK3CA mutation
- ●Hormone receptor positive (ER+/PR+)
- ●ESR1 ligand-binding domain mutation
- +6 more
Acute myeloid leukemia
7 biomarkers- ●FLT3 ITD
- ●IDH1 R132 mutation
- ●IDH2 R140/R172 mutation
- ●PML::RARA fusion (APL)
- ●FLT3 TKD (D835/I836)
- +2 more
Solid tumors
6 biomarkers- ●MSI-H / dMMR
- ●TMB-High (>=10 mut/Mb)
- ●NTRK gene fusion
- ●DPYD *13 — fluoropyrimidine toxicity
- ●DPYD *2A — fluoropyrimidine toxicity
- +1 more
Prostate cancer
4 biomarkers- ●BRCA1/2 pathogenic variant
- ●PSMA-positive (prostate cancer)
- ●HRR gene mutation (mCRPC)
- ●BRCA1/2 mutation (first-line mCRPC — PARP + AR combination)
Chronic myeloid leukemia
4 biomarkers- ●BCR::ABL1 fusion (Ph+)
- ●BCR::ABL1 T315I — asciminib indicated
- ●BCR::ABL1 T315I — resistance to TKIs
- ●BCR::ABL1 T315I — asciminib indicated
Acute lymphoblastic leukemia
4 biomarkers- ●BCR::ABL1 fusion (Ph+)
- ●TPMT reduced activity — thiopurine toxicity
- ●NUDT15 reduced activity — thiopurine toxicity
- ●TPMT / NUDT15 deficiency — thiopurine toxicity
Cholangiocarcinoma
3 biomarkers- ●IDH1 R132 mutation
- ●FGFR2 fusion / rearrangement
- ●IDH1 mutation (cholangiocarcinoma)
Ovarian cancer
2 biomarkers- ●BRCA1/2 pathogenic variant
- ●FRα / FOLR1 high expression (platinum-resistant ovarian cancer)
Gastrointestinal stromal tumor
2 biomarkers- ●KIT or PDGFRA mutation (GIST)
- ●PDGFRA D842V mutation (GIST)
Glioma
2 biomarkers- ●IDH1/IDH2 mutation (grade 2 glioma)
- ●IDH1/IDH2 mutation (low-grade glioma)
Myelodysplastic syndrome
2 biomarkers- ●Deletion 5q (myelodysplastic syndrome)
- ●SF3B1 mutation / ring sideroblasts (MDS)
Gastric adenocarcinoma
1 biomarker- ●HER2 overexpression / amplification (gastric or GEJ adenocarcinoma)
Chronic lymphocytic leukemia
1 biomarker- ●TP53 deletion / del(17p) (chronic lymphocytic leukemia)
Gastroenteropancreatic neuroendocrine tumor
1 biomarker- ●Somatostatin receptor 2 expression (GEP-NET)